STABLE AND HIGHLY CONCENTRATED FORMULATION OF THE ANTIBODY NIMOTUZUMAB

The present invention relates to the fields of biotechnology and medicine and describes high-concentration pharmaceutical formulations comprising the humanised monoclonal antibody nimotuzumab in a concentration range between 50 and 200 mg/mL. The low viscosity values of these solutions enable them t...

Full description

Saved in:
Bibliographic Details
Main Authors FERNANDEZ SAEZ, OLGA LIDEA, SANTO TOMAS POMPA, JULIO FELIPE, CEDENO ARIAS, MERCEDES, CASTILLO VITLOCH, ADOLFO, HERNANDEZ TERRERO, YAIKO SADDAN, LEON MONZON, KALET, RASHIDA DE LA LUZ HERNANDEZ, KATHYA, BOGGIANO AYO, TAMMY
Format Patent
LanguageEnglish
French
Published 24.06.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the fields of biotechnology and medicine and describes high-concentration pharmaceutical formulations comprising the humanised monoclonal antibody nimotuzumab in a concentration range between 50 and 200 mg/mL. The low viscosity values of these solutions enable them to be used subcutaneously or intramuscularly in cancer treatments. These formulations are stable in both liquid and freeze-dried forms. La présente invention concerne les domaines de la biotechnologie et de la médecine et décrit des formulations pharmaceutiques de haute concentration qui comprennent l'anticorps monoclonal humanisé nimotuzumab dans un niveau de concentration compris entre 50 et 200 mg/mL. Les faibles valeurs de viscosité de ces solutions permettent leur utilisation par voie sous-cutanée et intramusculaire dans le traitement du cancer. Ces formulations sont stables tant sous leurs formes liquides que sous leurs formes lyophilisées.
Bibliography:Application Number: CA20203163630